Dyadic International (DYAI) Net Cash Flow (QoQ) (2018 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Cash Flow (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.78 Bn | 192.79 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.92 Bn | 176.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.17 Bn | 1.37 Bn |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn |
| 8 | Biogen | 31.92 Bn | 30.63 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn |
| 10 | Dyadic International | 17.65 Mn | 9.69 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 46.45% |
| Dec 31, 2025 | -140.92% |
| Sep 30, 2025 | 391.47% |
| Jun 30, 2025 | 24.37% |
| Mar 31, 2025 | -344.17% |
| Dec 31, 2024 | 377.48% |
| Sep 30, 2024 | 95.20% |
| Jun 30, 2024 | -209.38% |
| Mar 31, 2024 | 556.18% |
| Dec 31, 2023 | -156.80% |
| Sep 30, 2023 | 393.42% |
| Jun 30, 2023 | -191.95% |
| Mar 31, 2023 | 162.92% |
| Dec 31, 2022 | 66.17% |
| Sep 30, 2022 | 7.01% |
| Jun 30, 2022 | 11.93% |
| Mar 31, 2022 | -257.81% |
| Dec 31, 2021 | 740.86% |
| Sep 30, 2021 | -100.00% |
| Jun 30, 2021 | 199.91% |